Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics (PRQR) Total Current Liabilities (2016 - 2025)

ProQR Therapeutics' Total Current Liabilities history spans 6 years, with the latest figure at $37.8 million for Q4 2025.

  • On a quarterly basis, Total Current Liabilities fell 9.16% to $37.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $37.8 million, a 9.16% decrease, with the full-year FY2025 number at $37.8 million, down 9.16% from a year prior.
  • Total Current Liabilities hit $37.8 million in Q4 2025 for ProQR Therapeutics, down from $41.6 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for PRQR hit a ceiling of $41.6 million in Q4 2024 and a floor of $12658.2 in Q1 2021.
  • Historically, Total Current Liabilities has averaged $27.2 million across 5 years, with a median of $28.1 million in 2022.
  • The widest YoY moves for Total Current Liabilities: up 210168.06% in 2022, down 33.52% in 2022.
  • Tracing PRQR's Total Current Liabilities over 5 years: stood at $31.6 million in 2021, then tumbled by 32.17% to $21.4 million in 2022, then surged by 71.86% to $36.8 million in 2023, then increased by 12.96% to $41.6 million in 2024, then decreased by 9.16% to $37.8 million in 2025.
  • Business Quant data shows Total Current Liabilities for PRQR at $37.8 million in Q4 2025, $41.6 million in Q4 2024, and $36.8 million in Q4 2023.